An interventional study of Active Low Field Magnetic Stimulation and Sham Low Field Magnetic Stimulation in Treatment Resistant Depression, sponsored by Weill Medical College of Cornell University. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-09-17.
Sponsored by Weill Medical College of Cornell University · Not applicable, Interventional, and Treatment
This is a double-blind, randomized, sham-controlled phase II study of the effects of Low Field Magnetic Stimulation (LFMS) on brain circuitry of adults with treatment-resistant Major Depressive Disorder (MDD). Eligible subjects will be randomly assigned to double-blind treatment with three 20 minute sessions of either (1) active LFMS or (2) sham LFMS. Resting state fMRI will be performed at baseline and following the third and final treatment session.
A minimum of 60 subjects will enter the double-blind treatment phase of the study. This trial will be conducted according to the U.S. Food and Drug Administration guidelines and the Declaration of Helsinki. Written informed consent will be obtained from all patients before protocol-specified procedures are carried out. The subjects will be drawn from an outpatient sample of patients with current Major Depressive Disorder (MDD) diagnosed with the use of the Mini International Neuropsychiatric Interview (MINI).
LFMS will follow a previously published protocol for the treatment of a Major Depressive Episode (Rohan et al. 2004). LFMS treatments will be delivered with a prototype LFMS device manufactured by Tal Medical. LFMS sessions consist of proton echo-planar magnetic resonance spectroscopic imaging (EP-MRSI) and will be 20min in duration. LFMS exposes subjects to magnetic fields of the same magnitude and frequency used in clinical MR-Spectroscopic imaging of the brain. Sham LFMS will consist of a three-dimensional spoiled gradient echo sequence of the same duration as active LFMS and which provides auditory stimulation indistinguishable from active treatment.
At the beginning of a treatment session, the subject will sit in front of and position his head within the open bore of the Tal Medical LFMS device. The device will be pre-programmed to deliver active or sham treatment so that the subject, operator, and all investigators are blinded to active treatment vs. sham. Immediately before and after each treatment session, the PANAS, Ham-D-6, and Visual Analog Mood Scale will be administered and the patient will be monitored for any adverse events.
All participants will undergo two sessions of neuroimaging: On the Friday prior to the first treatment session (Day 0) and on the day of the third and final treatment session (Day 7). Each session of neuroimaging will be 50 minutes in duration and include three imaging modalities: Resting State fMRI (rsfMRI), Arterial Spin Labeling MRI (ASL), and Diffusion Tensor Imaging (DTI). In addition, we will obtain high-resolution anatomical volumes (SPGR) for each subject for the purpose of transforming each individual's imaging data into a common space for group comparisons. Subjects will lie still in the scanner and will be instructed to let their mind "wander freely" during the acquisition of the resting state fMRI scan, which will last 6 minutes (Anon 2001). They will also be instructed to lie still during the ASL and DTI scans (each lasting 8 minutes). In addition, we will obtain a high-resolution T1-weighted (MP-RAGE) anatomical scan for co-registration of each individual's imaging data into a common space for group statistics..
Resting state fMRI will be used to measure the functional connectivity within the default mode network (DMN) and other circuits that are known to function abnormally in MDD (Greicius et al. 2007). ASL will be used to measure the regional blood flow within individual nodes of this circuitry, while DTI will measure the structural integrity of the connections between nodes. Measurements at baseline will be compared to measurements post-LFMS in both active treatment and sham groups.
8,055 studies on the registry are indexed under Depression; 1,643 are open to participants now.
This study's enrollment of 66 is below the median of 84 across 6,718 interventional studies indexed under Depression.
Browse Depression studies →Weill Medical College of Cornell University is the lead sponsor of 867 studies on the registry; 160 are open to participants now.
Of its 119 completed or terminated interventional studies of FDA-regulated products, 91 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
LFMS will follow a previously published protocol for the treatment of a Major Depressive Episode (Rohan et al. 2004). Active Low Field Magnetic Stimulation treatments will be delivered with a prototype LFMS device manufactured by Tal Medical. LFMS sessions consist of proton echo-planar magnetic resonance spectroscopic imaging (EP-MRSI) and will be 20min in duration. LFMS exposes subjects to magnetic fields of the same magnitude and frequency used in clinical MR-Spectroscopic imaging of the brain.
Device: Active Low Field Magnetic Stimulation
Sham Low Field Magnetic Stimulation will consist of a three-dimensional spoiled gradient echo sequence of the same duration as active LFMS and which provides auditory stimulation indistinguishable from active treatment.
Device: Sham Low Field Magnetic Stimulation
Active Low Field Magnetic Stimulation treatments will be delivered with a prototype LFMS device manufactured by Tal Medical. LFMS sessions consist of proton echo-planar magnetic resonance spectroscopic imaging (EP-MRSI) and will be 20min in duration. LFMS exposes subjects to magnetic fields of the same magnitude and frequency used in clinical MR-Spectroscopic imaging of the brain.
Sham Low Field Magnetic Stimulation will consist of a three-dimensional spoiled gradient echo sequence of the same duration as active LFMS and which provides auditory stimulation indistinguishable from active treatment.
6 Item Hamilton Depression Rating Scale
This is to compare the 6 Item Hamilton Depression Rating Scale from the Screen to after 3 Sessions of Active or Sham LFMS (7 days post-baseline). The Hamilton Scale for Depression 6 item subscale scores range from 0-24. Higher scores indicate greater severity of depression. Total scores are reported with no subscales.
Time frame: 7 days after baseline
Visual Analog Scale
A Visual Analog Scale is a measurement of subjective characteristics that cannot be directly measured. Using this self questionnaire, subjects specify their level of depression along a continuous line between two end-points ranging from 0-100 (higher score means better mood).
Time frame: 7 days after baseline
Positive and Negative Affect Score (PANAS) - Negative Subscale
The Positive and Negative Affect Schedule (PANAS) measures both positive affect and negative affect. Participants in the PANAS are required to respond to two 20-item subscales using 5-point scale that ranges from very slightly or not at all (1) to extremely (5). This negative subscale captures self-rated scale of symptoms of depression ranging from 0-50 (higher score means worse depression).
Time frame: 7 days after baseline
Positive and Negative Affect Score (PANAS) - Positive Subscale
The Positive and Negative Affect Schedule (PANAS) measures both positive affect and negative affect. Participants in the PANAS are required to respond to two 20-item subscales using 5-point scale that ranges from very slightly or not at all (1) to extremely (5). This positive subscale captures self-rated scale of symptoms of depression ranging from 0-50 (higher score means worse depression).
Time frame: 7 days after baseline
| Milestone | Active Low Field Magnetic Stimulation | Sham Low Field Magnetic Stimulation |
|---|---|---|
| Started | 34 | 32 |
| Completed | 34 | 32 |
| Not completed | 0 | 0 |
This is to compare the 6 Item Hamilton Depression Rating Scale from the Screen to after 3 Sessions of Active or Sham LFMS (7 days post-baseline). The Hamilton Scale for Depression 6 item subscale scores range from 0-24. Higher scores indicate greater severity of depression. Total scores are reported with no subscales.
| units on a scale | Active Low Field Magnetic Stimulation | Sham Low Field Magnetic Stimulation |
|---|---|---|
| 6 Item Hamilton Depression Rating Scale | 7.4 ± 3.4 | 7.6 ± 3.7 |
A Visual Analog Scale is a measurement of subjective characteristics that cannot be directly measured. Using this self questionnaire, subjects specify their level of depression along a continuous line between two end-points ranging from 0-100 (higher score means better mood).
| units on a scale | Active Low Field Magnetic Stimulation | Sham Low Field Magnetic Stimulation |
|---|---|---|
| Visual Analog Scale | 74 ± 20.6 | 59.4 ± 26.2 |
The Positive and Negative Affect Schedule (PANAS) measures both positive affect and negative affect. Participants in the PANAS are required to respond to two 20-item subscales using 5-point scale that ranges from very slightly or not at all (1) to extremely (5). This negative subscale captures self-rated scale of symptoms of depression ranging from 0-50 (higher score means worse depression).
| units on a scale | Active Low Field Magnetic Stimulation | Sham Low Field Magnetic Stimulation |
|---|---|---|
| Positive and Negative Affect Score (PANAS) - Negative Subscale | 15.8 ± 7.2 | 18.6 ± 7.4 |
The Positive and Negative Affect Schedule (PANAS) measures both positive affect and negative affect. Participants in the PANAS are required to respond to two 20-item subscales using 5-point scale that ranges from very slightly or not at all (1) to extremely (5). This positive subscale captures self-rated scale of symptoms of depression ranging from 0-50 (higher score means worse depression).
| units on a scale | Active Low Field Magnetic Stimulation | Sham Low Field Magnetic Stimulation |
|---|---|---|
| Positive and Negative Affect Score (PANAS) - Positive Subscale | 24.8 ± 8.7 | 25.5 ± 11.9 |
Collected over 7 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active Low Field Magnetic Stimulation | 1/34 (2.9%) | 0/34 (0%) | 1/34 (2.9%) |
| Sham Low Field Magnetic Stimulation | 0/32 (0%) | 0/32 (0%) | 0/32 (0%) |
| Event | Active Low Field Magnetic Stimulation | Sham Low Field Magnetic Stimulation |
|---|---|---|
| Panic AttackPsychiatric disorders | 1/34 | 0/32 |
| Age, Continuous(years) | Active Low Field Magnetic Stimulation | Sham Low Field Magnetic Stimulation | Total |
|---|---|---|---|
| Mean | 46.6 ± 15.1 | 46.2 ± 12.2 | 46.4 ± 13.65 |
| Sex: Female, Male(Participants) | Active Low Field Magnetic Stimulation | Sham Low Field Magnetic Stimulation | Total |
|---|---|---|---|
| Female | 17 | 20 | 37 |
| Male | 17 | 12 | 29 |
| Ethnicity (NIH/OMB)(Participants) | Active Low Field Magnetic Stimulation | Sham Low Field Magnetic Stimulation | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 5 | 9 |
| Not Hispanic or Latino | 30 | 27 | 57 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Active Low Field Magnetic Stimulation | Sham Low Field Magnetic Stimulation | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 8 | 15 |
| White | 26 | 22 | 48 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Active Low Field Magnetic Stimulation | Sham Low Field Magnetic Stimulation | Total |
|---|---|---|---|
| United States | 34 | 32 | 66 |
| Hamilton Scale for Depression (HamD) 6 Item(units on a scale) | Active Low Field Magnetic Stimulation | Sham Low Field Magnetic Stimulation | Total |
|---|---|---|---|
| Mean | 11.8 ± 1.7 | 11.4 ± 1.8 | 11.6 ± 1.75 |
| Visual Analog Scale(units on a scale) | Active Low Field Magnetic Stimulation | Sham Low Field Magnetic Stimulation | Total |
|---|---|---|---|
| Mean | 55.4 ± 19.9 | 49.9 ± 21.8 | 52.7 ± 20.1 |
| Positive and Negative Affect Score (PANAS) - Negative Subscale(units on a scale) | Active Low Field Magnetic Stimulation | Sham Low Field Magnetic Stimulation | Total |
|---|---|---|---|
| Mean | 23.7 ± 7.6 | 27.5 ± 8.9 | 25.6 ± 8.25 |
1 further baseline measures are reported on the registry.
Plan to share: No — Participants will be able to find out which treatment arm they were assigned at the conclusion of the study.
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Weill Medical College of Cornell University